Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28427406 | 0.84 | PARP1 (0.33) | KDM4EMEN1USP2ALDH1A1MAPT | |
| SCHEMBL2823571 | 0.83 | ALDH1A1 (0.33) | KDM4EMEN1USP2ALDH1A1MAPT | |
| SCHEMBL2823356 | 0.83 | PARP1 (0.36) | KDM4EALDH1A1PDE2APDE10APARP1 | |
| SCHEMBL2826725 | 0.81 | FABP3 (0.33) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL2823352 | 0.78 | PDE2A (0.31) | PDE2A | |
| SCHEMBL1148916 | 0.75 | PTGS1 (0.35) | KDM4EMEN1USP2ALDH1A1MAPT | |
| SCHEMBL1148948 | 0.75 | RXFP1 (0.45) | KDM4EMEN1USP2ALDH1A1MAPT | |
| SCHEMBL1148804 | 0.75 | MAPT (0.40) | KDM4EMEN1MAPTKMT2ALMNA | |
| SCHEMBL1148871 | 0.74 | ALDH1A1 (0.41) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL6700570 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386914-B1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-7022855-B2 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1559321-A1 | MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1386914-A1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | ATL3, RABL3, RAB5C | KDM4E 2031/4885MEN1 3131/4885USP2 1504/4885 |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | SF3A3, PEX3, HCN3 | KDM4E 1688/4885MEN1 2772/4885USP2 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.